MindMed doses first subject in trial of tablets for generalised anxiety disorder [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
The first of two Phase III trials, Voyage is designed to assess the therapy's safety and efficacy versus placebo among nearly 200 US subjects. It will be carried out in two segments, with the first being a randomised, placebo-controlled 12-week period and the second being a 40-week extension phase offering open-label treatment based on symptom severity. Change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) at week 12 is the trial's primary endpoint, aligning with the durable clinical effect observed in the Phase IIb study. MindMed chief medical officer Daniel Karlin said: “Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people in the US living with GAD. “Building on our scientifically rigorous Phase IIb study, which demonstrated efficacy that far exceeds today's standard of care and a favourable tolerability profile, our Phase III studies are designed to adhere to the highest clinical and ethical standards
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Novo Holdings completes purchase of Catalent [Seeking Alpha]Seeking Alpha
- Novo Holdings Completes Acquisition of Catalent [Yahoo! Finance]Yahoo! Finance
- Novo Holdings Completes Acquisition of CatalentBusiness Wire
- MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) [Yahoo! Finance]Yahoo! Finance
- Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- CTLT's page on the SEC website